renal cell carcinoma	is a type of	kidney cancer
papillary RCC	is a type of	renal cell carcinoma
chromophobe RCC	is a type of	renal cell carcinoma
clear cell RCC	is a type of	renal cell carcinoma
renal pelvis cancer	is a type of	urothelial carcinoma
kidney cancer	includes	renal cell carcinoma
kidney cancer	includes	urothelial carcinoma
renal cell carcinoma	originates in	renal cortex
renal pelvis cancer	originates in	urothelium
hematuria	is symptom of	kidney cancer
flank pain	is symptom of	kidney cancer
anemia	is paraneoplastic syndrome of	kidney cancer
hypercalcemia	is paraneoplastic syndrome of	kidney cancer
weight loss	is symptom of	kidney cancer
thrombocytosis	is paraneoplastic syndrome of	kidney cancer
smoking	is risk factor for	kidney cancer
obesity	is risk factor for	kidney cancer
hypertension	is risk factor for	kidney cancer
diabetes mellitus	is risk factor for	kidney cancer
occupational exposure	is risk factor for	urothelial carcinoma
aromatic amines exposure	is risk factor for	urothelial carcinoma
smoking	is risk factor for	urothelial carcinoma
VHL gene	is associated with	clear cell RCC
VHL mutation	is associated with	renal cell carcinoma
BAP1 mutation	is associated with	kidney cancer
MET mutation	is associated with	papillary RCC
FGFR3 mutation	is associated with	urothelial carcinoma
nephroureterectomy	is treatment for	renal pelvis cancer
radical nephrectomy	is treatment for	kidney cancer
partial nephrectomy	is treatment for	small renal mass
nephron-sparing surgery	is treatment for	small renal mass
nephrectomy	is treatment for	kidney cancer
nephroureterectomy	removes	kidney and ureter
bladder cuff excision	is part of	nephroureterectomy
systemic therapy	is used for	metastatic kidney cancer
immunotherapy	is used for	metastatic kidney cancer
nivolumab	is a	checkpoint inhibitor
pembrolizumab	is a	PD-1 inhibitor
atezolizumab	is a	PD-L1 inhibitor
targeted therapy	is used for	metastatic kidney cancer
sunitinib	is a	tyrosine kinase inhibitor
pazopanib	is a	tyrosine kinase inhibitor
axitinib	is a	tyrosine kinase inhibitor
cabozantinib	is a	tyrosine kinase inhibitor
temsirolimus	is a	mTOR inhibitor
everolimus	is a	mTOR inhibitor
carboplatin	is a	platinum-based chemotherapy
cisplatin	is a	platinum-based chemotherapy
chemotherapy	is used for	urothelial carcinoma
carboplatin	is used for	urothelial carcinoma
cisplatin	is used for	urothelial carcinoma
radiation therapy	is used for	urothelial carcinoma
surgery	is used for	localized kidney cancer
nephrectomy	removes	kidney
partial nephrectomy	preserves	renal function
nephron-sparing surgery	preserves	renal function
nephrectomy	results in	loss of kidney function
renal function	may decline after	nephrectomy
eGFR	decreases after	nephrectomy
lymph node metastasis	worsens	prognosis
distant metastasis	worsens	prognosis
stage IV disease	is associated with	poor prognosis
five-year survival	depends on	stage
tumor size	correlates with	prognosis
metastasis	indicates	advanced cancer
lung metastasis	is common site of	kidney cancer metastasis
bone metastasis	is possible in	kidney cancer metastasis
liver metastasis	is possible in	kidney cancer metastasis
brain metastasis	is possible in	kidney cancer metastasis
urine cytology	is used for	urothelial carcinoma detection
urine cytology	has limited sensitivity for	low-grade urothelial carcinoma
urinalysis	detects	microscopic hematuria
CT scan	localizes	renal mass
MRI	characterizes	renal mass
biopsy	confirms	renal mass diagnosis
percutaneous biopsy	confirms	renal mass diagnosis
histology	defines	tumor type
papillary RCC	has histology	papillary architecture
clear cell RCC	has histology	clear cytoplasm
chromophobe RCC	has histology	pale cytoplasm
kidney cancer	affects	adults
kidney cancer	more common in	older adults
kidney cancer	has comorbidity with	hypertension
kidney cancer	has comorbidity with	diabetes mellitus
cadmium exposure	is risk factor for	kidney cancer
arsenic exposure	is risk factor for	urothelial carcinoma
nephrectomy	reduces	renal function
nephron-sparing surgery	preserves	renal function
stage I disease	has	better prognosis
stage IV disease	has	poor prognosis
follow-up	includes	imaging
imaging	is used for	staging kidney cancer
staging	informs	treatment choice
treatment choice	depends on	stage
bladder recurrence	risk after	nephroureterectomy
bladder cuff	removed with	nephroureterectomy
renal pelvis tumor	presents with	hematuria
kidney tumor	presents with	flank pain
genetic predisposition	increases risk for	kidney cancer
sporadic cancer	differs from	hereditary cancer
